Aumolertinib plus bevacizumab for untreated advanced NSCLC with EGFR sensitive mutation
BackgroundAumolertinib is a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) with proven efficacy and safety for untreated non-small-cell lung cancer (NSCLC) patients with EGFR sensitizing mutations (EGFRm) in China. The progression-free survival (PFS) imp...
Gardado en:
| Principais autores: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Oncology |
| Assuntos: | |
| Acceso en liña: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1595812/full |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|